Glycoanalysis company ProCognia (Israel) Ltd. (TASE:PRCG) is providing glycosylation analysis products and services to the Biologics and Genetic Therapies Directorate of Health Canada, for research on biotherapeutic products. Procognia’s share price rose 7.8% by midday to NIS 0.538, giving a market cap of NIS 13 million.
Procognia CEO Dr. Ruth Ben-Yakar said, “We are very proud of Health Canada’s choice to use our glycosylation analysis products and services for research of various biotherapeutic products. We regard it as a vote of confidence in the capabilities of our technologies and of our services”.
For full article, please visit Globes Online.